

Best of UEG Week 2024 with Albrecht Neesse on "HPB";

Julia Mayerle

Podcast Episode

Hepatobiliary

November 13, 2024

UEG Week 2024 in Vienna featured new evidence on immediate necrosectomy for pancreatic necrosis, emerging metabolic treatments for liver disease, and the growing role of patient-reported outcomes in gastroenterology.

KEY POINTS

- The ACCELERATE trial from Denmark and WONDER-1 trial from Japan both suggest immediate necrosectomy after drainage may benefit selected patients with infected pancreatic necrosis, showing improved hospital stay and clinical success rates without mortality differences, though patient selection criteria remain to be defined.
- A retrospective study of over 900 patients from Göttingen found that proton pump inhibitor use was associated with increased lumen-opposing metal stent obstruction in pancreatic necrosis, suggesting PPIs may be detrimental, though prospective data are needed.
- Resmetirom, a thyroid hormone analogue approved by the FDA in March 2024 for MASH, was highlighted alongside non-invasive biomarkers like ProC3 to predict treatment response and GLP agonists showing positive liver effects.
- Patient-reported outcome measures, patient-reported experience measures, and prehabilitation programs are emerging as important topics for precision and value-based medicine in hepatopancreatic and biliary diseases.
- UEG Week 2025 in Berlin will feature a new Digestive Disease Mechanism Summit aimed at basic scientists to foster exchange with clinicians.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/a98d98e6-baf2-11ef-b5e8-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.